Resistance to microtubule targeting agents (MTA) represents a major drawback in successful cancer therapy with MTAs. Here we investigated the combined treatment modality of the novel MTA BAL101553 in combination with radiotherapy in paclitaxel and epothilone-resistant tumor models.
http://ift.tt/2uk0Srm
Δευτέρα 7 Αυγούστου 2017
The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου